Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

International Nonproprietary Names (INN) for pharmaceutical substances

S Kopp-Kubel1

  • 1Division of Drug Management and Policies, World Health Organization, Geneva Switzerland.

Bulletin of the World Health Organization
|January 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Compendial issues: WHO.

Journal of parenteral science and technology : a publication of the Parenteral Drug Associationยท1992
See all related articles

The World Health Organization (WHO) establishes international pharmaceutical standards and collaborates on drug nomenclature. This ensures patient safety by preventing trademark confusion with International Nonproprietary Names (INNs).

Area of Science:

  • Pharmaceutical sciences
  • Drug nomenclature
  • Biotechnology

Background:

  • The World Health Organization (WHO) is constitutionally mandated to develop international standards for biological and pharmaceutical products.
  • Accurate drug nomenclature is crucial for global pharmaceutical markets and patient safety, preventing confusion with trade names.
  • Existing nomenclature systems face challenges due to rapid advancements in pharmacology and biotechnology.

Purpose of the Study:

  • To outline the WHO's role in establishing international standards for pharmaceutical nomenclature.
  • To emphasize the importance of distinct International Nonproprietary Names (INNs) to avoid trade-mark conflicts and ensure patient safety.
  • To highlight the evolving challenges and new conceptual developments in pharmaceutical naming, particularly for biologics.

Related Experiment Videos

Main Methods:

  • Collaboration with national nomenclature committees to select globally acceptable names for active pharmaceutical substances.
  • Development of guidelines to prevent trade-mark derivation from INNs or common INN stems.
  • Exploration of new nomenclature schemes for novel pharmaceutical compounds, including monoclonal antibodies and recombinant products.

Main Results:

  • The WHO actively promotes standardized pharmaceutical naming through international collaboration.
  • Guidelines are in place to differentiate INNs from trade-marks, safeguarding against potential patient safety risks.
  • Innovative nomenclature strategies are being developed to address naming complexities arising from biotechnology.

Conclusions:

  • The WHO's work on International Nonproprietary Names (INNs) is vital for global pharmaceutical safety and trade.
  • Continuous adaptation of nomenclature principles is necessary to accommodate scientific progress in drug development.
  • The development of new naming conventions is essential for complex biological and recombinant pharmaceuticals.